pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,337 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1833Endpoints1420Fierce Biotech742BioSpace733BioPharma Dive541raps241onclive165fda recalls
therapy area
allOncology12628Rare Disease3289Immunology2966Cardiology2832Hematology2240Pulmonology2207
  • J&J to acquire Ollin Biosciences for $2.2 billion to advance bispecific eye drug OLN324 against Roche’s Vabysmo
    Johnson & Johnson announced it will buy Ollin Biosciences for an upfront $2.2 billion, with additional regulatory and commercial milestones that could bring total payments to about $3.3 billion. O…
    Fierce Biotech · 8h agoDealPositive↗ source
  • Helus Pharma's modified psilocybin meets primary and secondary goals in phase 3 depression trial
    Helus Pharma reported that its oral, chemically modified psilocybin candidate, HLP003, was tested in a phase 3 study of 222 patients with major depressive disorder. Participants received a single 1…
    Fierce Biotech · 8h agoPositive readoutPositive↗ source
← prev
page 1 of 134
next →
116
fda medwatch112
globenewswire health73
fda press59
Vaccines1821
Psychiatry & CNS1225
Ophthalmology1110
Endocrinology & Metabolism794
Pain784
Nephrology767
  • Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipeline
    Eli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…
    Fierce Biotech · 9h agoDealPositive↗ source
  • Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseases
    Biogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…
    Fierce Biotech · 8h agoDealPositive↗ source
  • Johnson & Johnson agrees to acquire eye-disease biotech Ollin Biosciences for up to $3.3 billion
    Johnson & Johnson announced Monday that it will purchase Ollin Biosciences, a biotech focused on eye diseases. The transaction is valued at up to $3.3 billion, representing one of the larger recen…
    Endpoints · 4h agoDealPositive↗ source
  • Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting rare blood cancers
    Eli Lilly announced it will acquire Calytrix Bio, a Massachusetts biotech, in a deal valued at up to $1.5 billion. Calytrix focuses on precision therapies for myeloproliferative neoplasms, includi…
    BioPharma Dive · 5h agoDealPositive↗ source
  • Flagship Pioneering invests £100 million to launch AI-focused biotech lab in London
    Flagship Pioneering, the life‑science investor behind Moderna, announced the creation of a new laboratory in London. The lab will concentrate on building AI‑native platform companies, using artifi…
    Endpoints · 6h agoDealPositive↗ source
  • Choosing the Right AI Infrastructure Is Key to Accelerating Future Drug Discoveries
    Scientific AI is reshaping drug discovery by allowing developers to predict molecule behavior and design new compounds using models trained on protein structures, genomic data, and experimental res…
    BioPharma Dive · 8h agoNeutral↗ source
  • Clinical AI pilots stall due to organizational environment, not technology
    Clinical teams are increasingly using artificial intelligence to draft regulatory paperwork, assist data review, shape trial design and interpret complex evidence. The technology is proving its val…
    BioPharma Dive · 8h agoNeutral↗ source
  • Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with Sanofi
    Seawolf Therapeutics, a San Diego-based DNA-therapy startup, announced a $100 million financing round as it emerges from stealth. The round was led by Versant Ventures with participation from MPM…
    BioPharma Dive · 8h agoDealPositive↗ source
  • Flagship Pioneering invests £100 million to launch AI-focused biotech incubation lab in London
    Flagship Pioneering announced a £100 million investment to establish its first AI-focused biotech incubation unit outside Cambridge, locating it in London. The new Flagship Origination Lab, U.K.,…
    Fierce Biotech · 11h agoDealPositive↗ source
  • Eli Lilly makes 14th acquisition of 2026, buying a blood-cancer biotech
    Eli Lilly announced it has acquired a blood‑cancer focused biotechnology company, marking its 14th acquisition in 2026. The deal reflects Lilly’s aggressive expansion strategy, funded by strong sa…
    Endpoints · 3h agoDealPositive↗ source
  • CG Oncology's oncolytic therapy shows positive Phase 3 results in non-muscle invasive bladder cancer
    CG Oncology announced that its oncolytic immunotherapy, cretostimogene grenadenorepvec, achieved its primary endpoints in a Phase 3 trial involving patients with non-muscle invasive bladder cancer.…
    Endpoints · 5h agoPositive readoutPositive↗ source
  • Sofinnova Partners raises €725 million for second crossover fund targeting late-stage European biotech firms
    Sofinnova Partners announced the closing of its second crossover fund with €725 million ($815 million) in commitments. The fund is designed to fill the financing gap for late-stage European biopha…
    Endpoints · 11h agoDealPositive↗ source
  • Sofinnova Partners raises €725M crossover fund to back later-stage European biotech firms
    Sofinnova Partners, a leading European life‑science venture firm, announced that it has closed a second crossover fund worth 725 million euros (about $815 million). The new vehicle, called Sofinnov…
    BioPharma Dive · 11h agoDealPositive↗ source
  • Chinese authorities dismiss two researchers after child dies in gene‑editing study
    Chinese authorities have dismissed two researchers involved in a gene‑editing study after a child participant died. State media reported the firings, showing the government's swift response to the…
    Fierce Biotech · 14h agoRegulatoryNegative↗ source
  • Tandem Diabetes Care gets FDA clearance for tubeless insulin delivery system with up to 7-day wear
    Tandem Diabetes Care announced that the FDA has cleared its Tandem Mobi system as a tubeless automated insulin delivery device. The clearance allows the device to be worn for up to seven days witho…
    Fierce Biotech · 15h agoRegulatoryPositive↗ source
  • China adds CAR-T therapy to national insurance list, slashing price to $40,000
    China has added a CAR-T therapy to its National Reimbursement Drug List, cutting the price to $40,000. The reduction brings the treatment within the scope of basic medical insurance, improving aff…
    Endpoints · 1h agoRegulatoryNeutral↗ source
  • San Diego’s Seawolf Therapeutics raises $100M to develop non-viral gene therapies for obesity, muscle loss and osteoporosis
    San Diego‑based Seawolf Therapeutics announced it has closed a $100 million financing round to fund its platform for non‑viral gene therapies. The company says its approach tackles a long‑standing…
    Endpoints · 8h agoDealPositive↗ source
  • New polymer lidding technologies aim to make pharmaceutical blister packs fully recyclable
    Pharmaceutical manufacturers are increasingly prioritizing sustainability in material selection, packaging design and end-of-life handling. The goal is to lower environmental impact while keeping p…
    BioPharma Dive · 8h agoPositive↗ source
  • Parker Institute CEO Karen Knudsen says cancer research faces translation challenges
    Karen Knudsen, who has a track record of reshaping medical organizations, is now leading the Parker Institute for Cancer Immunotherapy, a nonprofit that turned ten years old this year. In a recent…
    Endpoints · 2h agoNeutral↗ source
  • Aclaris Therapeutics’ bosakitug fails Phase 2 eczema trial, TSLP program dropped
    Aclaris Therapeutics announced that its experimental antibody bosakitug (ATI-045) did not meet the primary endpoint in a Phase 2 study for moderate-to-severe atopic dermatitis. The double‑blind Ad…
    Fierce Biotech · 10h agoNegative readoutNegative↗ source
  • Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
    The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.
    BioPharma Dive · 53m ago↗ source
  • CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
    CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.
    BioPharma Dive · 1h ago↗ source
  • J&J bets $2.2B on Ollin’s vision loss drug
    The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
    BioPharma Dive · 1h ago↗ source